EirGenix : To announce the acquisition of major assets. (Supplement of March 9, 2022 announcement)

 To announce the acquisition of major assets.
(Supplement of March 9, 2022 announcement)

1.Name and nature of the underlying assets (if preferred shares,
 the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):
 The rights of profit sharing of TSY0110 (EG12043).
 TSY0110 (EG12043) (proposed Kadcyla biosimilar),
 an antibody-drug conjugate (ADC).
 Usage: The treatment of HER2 overexpressing breast cancer.
2.Date of occurrence of the event:2022/03/22
3.Volume, unit price, and total monetary amount of the transaction:
 USD 30,000,000
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
 Formosa Pharmaceuticals, Inc.
 Other related party.
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:
 The reason for choosing the related party as trading
 counterparty :
 To strengthen the strategic partnership.
 The identity of the previous owner, its relationship with
 the Company and the trading counterparty, and the previous
 date and monetary value of transfer:
 Not applicable.
6.Where an owner of the underlying assets within the past
 five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:
 Not applicable.
7.Matters related to the current disposal of creditors'
 rights (including types of collaterals of the disposed
creditor's rights; if creditor's rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor's
rights, currently being disposed of, over such related
party:
 Not applicable.
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
 explained):
 Not applicable.
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
 and other important terms and conditions:
 USD 30,000,000
 Based on the contract payment term.
 Restrictive covenants in the contract,
 and other important terms and conditions:
 None.
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
 Transaction: Price negotiation.
 The reference basis for the decision on price:
 The valuation report of major assets by GoodIP
 Intellectual Property Rights Office.
 The decision-making department:
 Board meeting.
11.Net worth per share of the Company's underlying securities
acquired or disposed of:
 Not applicable.
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
 and status of any restriction of rights (e.g., pledges),
 as of the present moment:
 Not applicable.
13.Ratio of securities investment (including the current
 transaction) to the total assets and shareholder's equity
 of the parent company on the latest financial statements,
 and the operating capital on the latest financial statements,
 as of the present moment:
 Not applicable.
14.Broker and broker's fee:
 Not applicable.
15.Concrete purpose or use of the acquisition or disposal:
 To strengthen the strategic partnership.
16.Whether the directors expressed any objection to the current
 transaction:
 None.
17.Whether the counterparty of the current transaction
is a related party:
 Yes.
18.Date of the Board of Directors' resolution:2022/03/22
19.Date of ratification by supervisors or approval by
the Audit Committee:2022/03/22
20.Whether the CPA issued an opinion on the unreasonableness
 regarding the current transaction:
 No.
21.Name of the CPA firm:
 Horng Yow C.P.A.s
22.Name of the CPA:
 Ru-You, Tang
23.License no.of the CPA:
 Financial Supervisory Commission(official letter No.0970013154).
24.Any other matters that need to be specified:
 None.